A T2-weighted MRI grading system for preoperative prediction of visceral pleural invasion in small non-small cell lung cancers

用于术前预测小非小细胞肺癌脏层胸膜侵犯的T2加权MRI分级系统

阅读:1

Abstract

PURPOSE: To evaluate the supplemental diagnostic value of T2WI for assessing VPI in NSCLC ≤3 cm with indeterminate CT features (pleural contact/tags). MATERIALS AND METHODS: This prospective single-center study enrolled 138 participants with NSCLC ≤3 cm and CT-suspected pleural involvement, of whom 98 underwent surgical resection and histopathologic VPI confirmation from January 2021 to March 2023. All participants underwent thoracic MRI (3.0T), including T2WI sequences. Two radiologists independently graded tumor-pleural interface signals (Grades 0-3: absent to wedge-shaped hyperintensity). Pathologic VPI served as the reference standard. Logistic regression and ROC analysis were performed to develop a predictive model integrating tumor size and T2WI grades. RESULTS: VPI-positive lesions (35/98, 35.7%) demonstrated larger mean tumor size (22.32 ± 5.58 mm vs. 16.17 ± 4.22 mm; P = 0.024) and higher T2WI hyperintensity frequencies (85.71% vs. 52.38%; P = 0.001). Grade 3 T2WI signals (wedge-shaped) achieved 93.65% specificity and 76.47% PPV for VPI, with a positive likelihood ratio of 5.85. Multivariate analysis identified tumor size (OR = 1.126/mm, P = 0.024), Grade 2 (OR = 8.826, P = 0.003), and Grade 3 signals (OR = 29.890, P < 0.001) as independent VPI predictors. The combined model achieved an AUC of 0.837 (95% CI: 0.758-0.916), demonstrating superior diagnostic performance versus CT-based criteria. CONCLUSION: T2WI-based grading of tumor-pleural interface hyperintensity serves as a radiation-free method for preoperative VPI prediction in small NSCLC, offering potential as a complementary tool to CT diagnosis. While promising, these findings require multicenter validation due to the single-center design.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。